치료 불응성 갑상선암에 대한 실험적 치료 약제: Histone Deacetylase Inhibitor, PPAR-gamma Agonist, Retinoic Acid

• 영문명: New Promising Therapeutic Modalities for Thyroid Cancers: Histone Deacetylase Inhibitor, PPAR-gamma Agonist, and Retinoic Acid
• 발행기관: 대한내분비외과학회
• 저자명: 정웅윤 OrloHClark¹ Woung Youn Chung M.D. and Orlo H Clark M.D.¹
• 간행물 정보: 『The Koreran journal of Endocrine Surgery』5권2호, 69~74쪽, 전체 6쪽
• 주제분류: 의약학 > 면역학
• 파일형태: PDF
• 발행일자: 2005.12.30

영문 초록

Most patients with thyroid cancer have well differentiated tumors that usually respond to conventional therapy including total or near total thyroidectomy, radioiodine ablation and TSH suppression. About 10% of patients, however, have aggressive cancers as a consequence of de-differentiation. During de-differentiation, thyroid cancers not only show more mitosis, fibrosis, and altered cell structure, they also lose thyroid-specific functions (iodine uptake, TSH receptor expression, and thyroglobulin production). These poorly differentiated or undifferentiated tumors mostly fail to take up radioiodine and are responsible for most deaths from thyroid cancer. New therapies need to be developed for patients with these types of tumors. Among the most promising antineoplastic therapies for these poorly differentiated and undifferentiated thyroid cancers are the histone deacetylase inhibitors, the PPAR-gamma agonist and retinoic acids. These drugs have therapeutic effects for thyroid cancers in inhibiting growth and inducing apoptosis and redifferentiation, in vivo and in vitro studies. And, clinical trials in patients with refractory thyroid cancers have been initiated. Further laboratory investigation of these drugs is necessary to understand molecular mechanisms and demonstrate therapeutic efficacy for thyroid cancers. (Korean J Endocrine Surg 2005;5:69-74)

키워드

치료 불응성 갑상선암, 재분화 치료,Thyroid cancer, Histone deacetylase inhibitors, The PPAR-gamma agonist, Retinoic acid, Redifferentiation